biostudies-literatureUnknown80(1)Schwamm LH<h4>Importance</h4>The Stroke of Known Cause and Underlying Atrial Fibrillation (STROKE AF) trial found that approximately 1 in 8 patients with recent ischemic stroke attributed to large- or small-vessel disease had poststroke atrial fibrillation (AF) detected by an insertable cardiac monitor (ICM) at 12 months. Identifying predictors of AF could be useful when considering an ICM in routine poststroke clinical care.<h4>Objective</h4>To determine the association between commonly assessed risk factors and poststroke detection of new AF in the STROKE AF cohort monitored by ICM.<h4>Design, setting, and participants</h4>This was a prespecified analysis of a randomized (1:1) clinical trial that enrolled patients between April 1, 2016, and July 12, 2019, with primary follow-up through 2020 and meJAMA neurology99-103https://www.ebi.ac.uk/biostudies/studies/S-EPMC9664367biostudies-literaturePredictors of Atrial Fibrillation in Patients With Stroke Attributed to Large- or Small-Vessel Disease: A Prespecified Secondary Analysis of the STROKE AF Randomized Clinical Trial.PMC9664367Whang WWright PPatel ABernard MSchwamm LHDillon GTempro KMarulanda-Londono EKipta JCaprio FLaFranchise EAl Balushi ADeline CWillner JTalpur NMagadan ASheinart KAlkahalifah MFayad PBRempe DKatz LLynch JBledsoe DRamirez DYuan QMaccaro PCBernabei MKatz JRasmussen JGibson DMatos Diaz IAl-Awwad AAsdaghi NMitrani RMemon ZMiller MChoudry SPakala ASawyer RSTROKE AF InvestigatorsStein LJadonath RHasan RChoudhuri IReeves RDhamoon MDonsky AMiles WMHasabnis SMesse SGraybeal DBanchs JChiu DKamel HWeinberger JZhu DBeaver BKaur GNeisen KGadhia RSilverman SZimmerman JOlson NStavrakis SChaudhary SChaudhary GMir OBonaguidi HSilverman SBArora RCarter JFurer SParker MMagun RSur NGadient PKoch SNiazi ISteinberg JSSwitzer DBonyak KSchaller RSharma RZiegler PDEtherton MAlsorogi MManda SRamano JChokhawala HMcclelland NSharma JSoik DBoyd CParker BReddy RDukkipati SReddy VBernstein RAFlaster MMoye SHeist EKMerriam TTSloane KGranger CBJohnson MThavapalan VCulpepper APolin GAssar MKreger HSethi PPJia JDelpirou Nouh CArias VJamal SAcosta IAlimohammad RMorris KHorowitz DSajjad RKearney MGoltz DKalia JLuciano JFranco NRami TMalik MKatz JMBelt GDash SSimonson JPassman RGarabelli PHao QRadoslovich GCajavilca CFara MAsi KMalik AGlotzer TMendelson SSackett MZhang CDoshi ARay BEpstein LKoruth JRowe SMerriam TKandel AMcCall-Brown AVidal GLambrakos LMattera BViswanathan AFelberg RGrimes MRKalafut MSeeger SKim CLee ROrtiz GTorres LRuff IThomas ATorres JKrueger KTuhrim SSkalabrin EDeo RThomas KOstrander MCross JHussein HChang CTansy ABlack JDowney ACucchiara BCheung PSingh DKim SZweifler RWilder MChinitz LLibman RAbi-Samra FFrankel DJung RKurian CMendoza ISidorov EBansal SBhatt NSaucedo SAllred JJamnadas PHanna JSidorov EVChing MShang TSethi PLubitz SMowla AIshida KGraner SShultz JMoussavi MBeldner SGuerrero WSaltzman MZide KMeisel KKasner SEHourihane JMMullen MMullins SBarrett CIsmail HWard KLillemoe KBadhwar NOlsovsky GClayton SRogers PLogan WSalem RMorin DAroor SRogers JDel Brutto VKasner SShukla GUddin PChancellor BDaniels JKhatib SRegenhardt RRowley CSmith MNguyen CPiccini JPLord AGordon DSantangeli PSmith WLangan MNPickett RADVolpi JfalsePredictors of Atrial Fibrillation in Patients With Stroke Attributed to Large- or Small-Vessel Disease: A Prespecified Secondary Analysis of the STROKE AF Randomized Clinical Trial.<h4>Importance</h4>The Stroke of Known Cause and Underlying Atrial Fibrillation (STROKE AF) trial found that approximately 1 in 8 patients with recent ischemic stroke attributed to large- or small-vessel disease had poststroke atrial fibrillation (AF) detected by an insertable cardiac monitor (ICM) at 12 months. Identifying predictors of AF could be useful when considering an ICM in routine poststroke clinical care.<h4>Objective</h4>To determine the association between commonly assessed risk factors and poststroke detection of new AF in the STROKE AF cohort monitored by ICM.<h4>Design, setting, and participants</h4>This was a prespecified analysis of a randomized (1:1) clinical trial that enrolled patients between April 1, 2016, and July 12, 2019, with primary follow-up through 2020 and me2023-01-01T00:00:00Z2023 Jan2026-05-27T18:52:10.211Z2025-02-19T01:07:53.577ZS-EPMC96643673637450810.1001/jamaneurol.2022.4038